The tweet was deleted by the author.
But we saved everything 🙂.
Upstream Bio, Inc. has unveiled additional analyses from the VIBRANT Phase 2 trial of verekitug targeting chronic rhinosinusitis with nasal polyps at the AAAAI2026 conference.
The presentation highlights ongoing research efforts aimed at addressing treatment gaps in chronic rhinosinusitis with nasal polyps, a condition that significantly impacts patient quality of life. The latest findings build on previously reported data, offering new insights into the efficacy and safety profile of verekitug in this patient population.